NUVAILA Trademark

Trademark Overview

On Tuesday, June 4, 2024, a trademark application was filed for NUVAILA with the United States Patent and Trademark Office. The USPTO has given the NUVAILA trademark a serial number of 98583378. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Wednesday, January 7, 2026. This trademark is owned by Optum Health Solutions (Ireland) Limited. The NUVAILA trademark is filed in the Advertising, Business and Retail Services category with the following description:

Procurement, namely, purchasing pharmaceuticals for others; Pharmaceutical commercialization services, namely, procuring biosimilar pharmaceuticals and selling pharmaceuticals to wholesale pharmaceutical distributors
nuvaila

General Information

Serial Number98583378
Word MarkNUVAILA
Filing DateTuesday, June 4, 2024
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateWednesday, January 7, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 14, 2025

Trademark Statements

Goods and ServicesProcurement, namely, purchasing pharmaceuticals for others; Pharmaceutical commercialization services, namely, procuring biosimilar pharmaceuticals and selling pharmaceuticals to wholesale pharmaceutical distributors

Classification Information

International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateTuesday, June 4, 2024
Primary Code035
First Use Anywhere DateMonday, January 6, 2025
First Use In Commerce DateMonday, January 6, 2025

Trademark Owner History

Party NameOptum Health Solutions (Ireland) Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDublin D01X9R7
IE
Party NameOptum Health Solutions (Ireland) Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDublin D01X9R7
IE

Trademark Events

Event DateEvent Description
Tuesday, June 4, 2024NEW APPLICATION ENTERED
Sunday, December 15, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 16, 2024ASSIGNED TO EXAMINER
Tuesday, December 17, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 8, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 14, 2025PUBLISHED FOR OPPOSITION
Tuesday, January 14, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 11, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, May 2, 2025TEAS STATEMENT OF USE RECEIVED
Thursday, August 28, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, August 28, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, August 28, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, August 28, 2025TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, September 29, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, May 2, 2025USE AMENDMENT FILED
Monday, September 29, 2025STATEMENT OF USE PROCESSING COMPLETE
Monday, November 3, 2025SU - NON-FINAL ACTION - WRITTEN
Monday, November 3, 2025NON-FINAL ACTION E-MAILED
Monday, November 3, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, December 17, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 6, 2026ASSIGNED TO LIE
Tuesday, January 6, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 6, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 6, 2026APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, January 7, 2026ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, January 7, 2026NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

Related Keywords

nuvaila pharmaceuticals pharmaceutical namely biosimilar selling wholesale distributors procuring commercialization purchasing